Provided by Tiger Fintech (Singapore) Pte. Ltd.

IO Biotech, Inc.

1.55
-0.0500-3.12%
Post-market: 1.550.00000.00%16:04 EDT
Volume:240.32K
Turnover:366.61K
Market Cap:102.12M
PE:-1.04
High:1.61
Open:1.61
Low:1.47
Close:1.60
Loading ...

IO Biotech Advances Phase 3 Trial and Secures Financing

TIPRANKS
·
05 Mar

IO Biotech Reports 2024 Business Highlights

GlobeNewswire
·
05 Mar

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

GlobeNewswire
·
24 Feb

IO Biotech announces publication of preclinical data on IO112

TIPRANKS
·
04 Feb

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

GlobeNewswire
·
04 Feb

IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma

MT Newswires Live
·
10 Jan

IO Biotech completes enrollment in Phase 2 trial of IO102-IO103

TIPRANKS
·
09 Jan

IO Biotech Inc - Initial Data From Phase 2 Trial Expected in 2025

THOMSON REUTERS
·
09 Jan

IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer

THOMSON REUTERS
·
09 Jan

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

GlobeNewswire
·
09 Jan

BRIEF-IO Biotech Receives Nasdaq Notice For Minimum Bid Price Non-Compliance

Reuters
·
28 Dec 2024

IO Biotech Inc - Receives Nasdaq Notice for Minimum Bid Price Non-Compliance

THOMSON REUTERS
·
28 Dec 2024

BRIEF-Io Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank

Reuters
·
20 Dec 2024

IO Biotech secures up to EUR 57.5M in debt financing

TIPRANKS
·
20 Dec 2024

IO Biotech Inc: Funds Expected to Be Used to Advance IO Biotech's Immune-Modulating Therapeutic Cancer Vaccines

THOMSON REUTERS
·
20 Dec 2024

IO Biotech Secures up to €57.5 Million in Debt Financing From the European Investment Bank

THOMSON REUTERS
·
20 Dec 2024

IO Biotech Inc: Debt Facility Expected to Extend Company's Cash Runway Into Q2 of 2026

THOMSON REUTERS
·
20 Dec 2024

Press Release: IO Biotech secures up to EUR57.5 million in debt financing from the European Investment Bank

Dow Jones
·
20 Dec 2024